Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Doctors show 'significant interest' in Boston's Watchman

This article was originally published in Clinica

Executive Summary

It may have only been approved just over a week ago, but clinicians are already showing a strong interest in Boston Scientific’s Watchman, according to an analyst survey. The device is designed to prevent stroke by closing the left-atrial appendage (LAA), a bulge in the wall of the left atrium of the heart where blood clots can form in patients with atrial fibrillation (AF).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT102479

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel